Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of PRO-174 Ophthalmic Solution in Healthy Subjects
NCT03519516Phase 1Completed
- Sponsor
- Laboratorios Sophia
- Start
- Jan 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of levofloxacin in bacterial conjunctivitis (BC) (2 arms), sponsored by Laboratorios Sophia. Primary endpoints: Number of Adverse Events at 12 days and Ocular Burning at 7 days. Started Jan 2018; status: completed.
02
Drugs
levofloxacin
03
Conditions
bacterial conjunctivitis (BC)
Beyond the preview
Go deeper on NCT03519516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03519516.